Navitoclax
- Generic Name
- Navitoclax
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H55ClF3N5O6S3
- CAS Number
- 923564-51-6
- Unique Ingredient Identifier
- XKJ5VVK2WD
- Background
Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.
...
- Associated Conditions
- -
- Associated Therapies
- -
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT04472598
- Locations
- π¨π¦
Lakeridge Health - Oshawa /ID# 222080, Oshawa, Ontario, Canada
πΊπΈIndiana Blood & Marrow Transpl /ID# 221586, Indianapolis, Indiana, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center /ID# 217994, Houston, Texas, United States
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 295
- Registration Number
- NCT04468984
- Locations
- πΊπΈ
Hospital of the University of Pennsylvania /ID# 219001, Philadelphia, Pennsylvania, United States
π¨π¦Princess Margaret Cancer Centre /ID# 253942, Toronto, Ontario, Canada
π¦πΉKlinikum Wels-Grieskirchen GmbH /ID# 220915, Wels, Oberoesterreich, Austria
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT04454658
- Locations
- π¦πΊ
Royal Perth Hospital /ID# 241678, Perth, Western Australia, Australia
πΊπΈThe Mount Sinai Hospital /ID# 221549, New York, New York, United States
πΊπΈUniversity of Oklahoma, Stephenson Cancer Center /ID# 224095, Oklahoma City, Oklahoma, United States
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 85
- Registration Number
- NCT04041050
- Locations
- πΊπΈ
Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
πΊπΈMoores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
πΊπΈCity of Hope /ID# 239769, Duarte, California, United States
Expanded Access to Navitoclax
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03592576
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 191
- Registration Number
- NCT03222609
- Locations
- πΊπΈ
University of Southern California /ID# 164095, Los Angeles, California, United States
πΊπΈDana-Farber Cancer Institute /ID# 162675, Boston, Massachusetts, United States
π¨π¦Princess Margaret Cancer Centre /ID# 214483, Toronto, Ontario, Canada
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 69
- Registration Number
- NCT03181126
- Locations
- πΊπΈ
City of Hope /ID# 169029, Duarte, California, United States
πΊπΈLPCH Stanford /ID# 163337, Palo Alto, California, United States
πΊπΈUniversity of Chicago /ID# 163369, Chicago, Illinois, United States
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT02520778
- Locations
- πΊπΈ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
πΊπΈRutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
πΊπΈBrigham and Women's Hospital, Boston, Massachusetts, United States
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT02143401
- Locations
- πΊπΈ
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
πΊπΈUniversity of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
πΊπΈMayo Clinic in Rochester, Rochester, Minnesota, United States
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: DabrafenibProcedure: EchocardiographyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanOther: Pharmacological StudyBiological: NavitoclaxDrug: Trametinib
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT01989585
- Locations
- πΊπΈ
University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
πΊπΈNorthwestern University, Chicago, Illinois, United States
πΊπΈUM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.